资源描述：
《全球生物科技与制药业专家会议纪要.docx》由会员上传分享，免费在线阅读，更多相关内容在行业资料-天天文库。
1、EquityResearchAmericas
2、UnitedStatesGlobalBiotechnology&PharmaPhysicianExpertCallTranscripttodiscussAlpha-1AntitrypsinDeficiencyPharmaceuticals&Biotechnology
3、ConferenceCallAspartofourBiotechPudding(ourweeklycallseries),wehostedDr.KyleHogarththisweektodiscussAlpha-1Antitrypsin(AAT)De
4、ficiency.Westartedwithadiseaseteach-in,followedbyadiscussionofcurrentandemergingtherapeuticsforthecondition.Wealsodiscussedthephase2programofVertex’sVX-814,expectationsintothedata,andthoughtsintowhatapivotalprogramcouldlooklike.Afulltranscriptofthecallcanbefoundwithinthisdocument.A
5、replayofthecallisavailable:(855)859-2056/(404)537-3406
6、ID:4582487.ResearchAnalystsEvanSeigerman2123254463evan.seigerman@credit-suisse.comEuropeanPharmaTeam442078880304creditsuisse.pharmateam@credit-suisse.comMatthewTerwelp,MD2123253493matthew.terwelp@credit-suisse.comDISCLOSUREAPP
7、ENDIXATTHEBACKOFTHISREPORTCONTAINSIMPORTANTDISCLOSURES,ANALYSTCERTIFICATIONS,LEGALENTITYDISCLOSUREANDTHESTATUSOFNON-USANALYSTS.USDisclosure:CreditSuissedoesandseekstodobusinesswithcompaniescoveredinitsresearchreports.Asaresult,investorsshouldbeawarethattheFirmmayhaveaconflictofinte
8、restthatcouldCREDITSUISSESECURITIES,LLCModerator:EvanSeigermanJune12,20208:30a.m.ETOperator:ThisisConference#:4582487Operator:Ladiesandgentlemen,thankyouforstandingby.AndwelcometheCreditSuisseExpertCalltodiscusstheAlpha-1AntitrypsinDeficiency.Atthistime,allparticipantsareinalisteno
9、nlymode.Afterthespeaker’spresentationtherewillbeaquestionandanswersession.Toaskaquestionduringthesessionyouneedtopress“star”,“1”onyourtelephone.Asaremindedtoday’scallisbeingrecorded.Ifyourequireoperatorassistanceplease“star”and“0”.Iwouldnowliketo(inaudible)today’sconferencecall,Mr.
10、EvanSeigerman,youmaybegin.EvanSeigerman:Hi,everyoneandthankyouforjoiningustoday.Iknowit’sabusyFridaybutwe’reveryhappytohaveDr.KyleHogarthwithustogiveusateachingonAlpha-1AntitrypsinDeficiencyandtalkaboutkeycomponentsofthediseasefromdiagnostictocurrenttherapeutics.Andthenofcourseemer
11、gingtherapeuticsincludingV
